Can Weight-Loss Medicines Help With Sleep Apnoea?
If someone snores loudly, stops breathing for a few seconds in their sleep, and wakes up tired every morning, they might have a condition called obstructive sleep apnoea, or OSA for short. It's common in the UK, and it's much more likely to happen in people who are living with obesity. New research is looking at whether weight-loss medicines could help. Here's what the evidence actually shows, and what it means if you live in the UK.
What is sleep apnoea?
"Apnoea" just means "no breathing." During sleep, the muscles in your throat relax. In most people, the airway stays open. But in people with OSA, extra fat around the neck and throat can make the airway narrow or collapse. The airway blocks, breathing stops for a moment, and the brain wakes the body up slightly to reopen it. This can happen dozens of times an hour, all night, without the person even remembering it.
The result is poor-quality sleep, loud snoring, and exhaustion during the day. Over time, untreated OSA is also linked to higher blood pressure, heart problems, and a higher risk of accidents caused by tiredness.
Doctors measure how bad OSA is using something called the apnoea-hypopnoea index, or AHI. This counts how many breathing pauses happen, on average, for every hour of sleep. A higher number means more severe OSA.
Why would a weight-loss medicine help?
Carrying extra weight, especially around the neck and upper body, is one of the biggest risk factors for OSA. So if a medicine helps someone lose a significant amount of weight, it makes sense that it might also ease the pressure on the airway and reduce breathing pauses at night.
This is exactly what a major clinical trial called SURMOUNT-OSA set out to test. It studied tirzepatide, the medicine prescribed in the UK as Mounjaro, in 469 adults with obesity and moderate-to-severe OSA. Some took tirzepatide, others took a dummy (placebo) injection, for 52 weeks.
The results were striking. In one part of the trial, people taking tirzepatide saw their AHI drop by an average of 55% more than those on placebo, alongside an average weight loss of around 18% of their starting body weight. In another part of the trial, the AHI dropped by nearly 63% more than placebo. Some participants improved so much that their sleep apnoea was reclassified as mild, or disappeared from the test results altogether.
So is it licensed for sleep apnoea in the UK?
This is the important bit for UK readers. In the United States, the FDA looked at this same trial evidence and approved tirzepatide (sold there as Zepbound) specifically to treat moderate-to-severe OSA in adults with obesity.
In the UK and the rest of Europe, regulators took a different approach. The European Medicines Agency reviewed the same data and decided not to create a separate licence for sleep apnoea. Its reasoning was that the benefit comes from weight loss, which is already covered by tirzepatide's existing licence for weight management, so a new, standalone licence wasn't considered necessary. Instead, the sleep apnoea trial data was simply added to the medicine's official product information, so doctors have it to hand.
In practice, this means Mounjaro is licensed in Great Britain for type 2 diabetes and for weight management in adults with obesity (or who are overweight with a related health problem). Obstructive sleep apnoea is listed as one example of the kind of weight-related problem that can make someone eligible for the weight-management licence, but it is not, on its own, an approved reason to prescribe the medicine for OSA specifically.
What this means if you have sleep apnoea
If you have OSA and obesity, and you're interested in weight-loss medication, a doctor will still need to assess you properly against the usual NHS or private eligibility criteria for weight management, which can include OSA as one of the qualifying conditions. NICE's current guidance on managing OSA does not recommend these medicines as a first-line or stand-alone sleep apnoea treatment. Tools like CPAP machines, which gently push air into the airway overnight, remain the main NHS treatment for OSA itself.
Weight-loss medicines are not a replacement for a proper sleep apnoea diagnosis or treatment plan, and they are not something to buy or try without medical supervision. They need a full assessment by a qualified clinician, who can weigh up your overall health, other conditions, and the right treatment route for you, whether that's through the NHS or a registered private prescriber.
The science here is genuinely encouraging, showing that tackling weight can have knock-on benefits for conditions like OSA. But in the UK, it's being treated as a welcome side effect of weight management, not yet an approved treatment for sleep apnoea in its own right.
Comments